, Volume 40, Issue 4, pp 531–542 | Cite as

Current Concepts in the Treatment of Immune Thrombocytopenia

  • Theodore E. Warkentin
  • John G. Kelton
Practical Therapeutics


Platelet destruction by antibodies is a common cause, of thrombocytopenia. In this review, various treatments for immune thrombocytopenia are discussed, with emphasis on corticosteroids, splenectomy, danazol, high-dose immunoglobulin G, anti-Rhesus globulin, colchicine and cytotoxic, immuftosuppressive agents such as cyclophosphamide and azathioprine. An approach to the treatment of adult idiopathic thrombocytopenic purpura (ITP) is reviewed in detail and the treatments for several other immune thrombocytopenic disorders are summarised.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abrams DI, Kiprov DD, Goedert JJ, Saragadharan MG, Gallo RC, et al. Antibodies to human T-lymphotropic virus type III and development of the acquired immunodeficiency syndrome in homosexual men presenting with immune thrombocytopenia. Annals of Internal Medicine 104: 47–50, 1986PubMedGoogle Scholar
  2. Adner MM, Fisch GR, Starobin SG, Aster RH. Use of ‘compatible’ platelet transfusions in treatment of congenital isoimmune thrombocytopenic purpura. New England Journal of Medicine 280: 244–247, 1969PubMedGoogle Scholar
  3. Ahn YS, Harrington WJ, Seelman RC, Eytel CS. Vincristine therapy of idiopathic and secondary thrombocytopenias. New England Journal of Medicine 291: 376–380, 1974PubMedGoogle Scholar
  4. Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall RM, et al. Danazol for the treatment of idiopathic thrombocytopenic purpura. New England Journal of Medicine 308: 1396–1399, 1983PubMedGoogle Scholar
  5. Ahn YS, Mylvaganam R, Garcia RO, Kim CI, Palow D, et al. Low-dose danazol therapy in idiopathic thrombocytopenic purpura. Annals of Internal Medicine 107: 177–181, 1987PubMedGoogle Scholar
  6. Ahn YS, Rocha R, Mylvaganam R, Garcia R, Duncan R, et al. Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. Annals of Internal Medicine 111: 723–729, 1989PubMedGoogle Scholar
  7. Akwari OE, Itani KM, Coleman RE, Rosse WF. Splenectomy for primary and recurrent immune thrombocytopenic purpura (ITP): current criteria for patient selection and results. Annals of Surgery 206: 529–541, 1987PubMedGoogle Scholar
  8. Ambriz P, Munoz R, Quintanar E, Sigler L, Aviles A, et al. Accessory spleen compromising response to splenectomy for idiopathic thrombocytopenic purpura. Radiology 155: 793–796, 1985PubMedGoogle Scholar
  9. Ambriz R, Munoz R, Pizzuto J, Quintanar E, Morales M, et al. Low-dose autologous in vitro opsonized erythrocyte: radioimmune method and autologous opsonized erythrocytes for refractory autoimmune thrombocytopenic purpura in adults. Archives of Internal Medicine 147: 105–108, 1987PubMedGoogle Scholar
  10. Ambriz R, Pizzuto J, Morales M, Chavez G, Guillen C, et al. Therapeutic effect of danazol on metrorrhagia in patients with idiopathic thrombocytopenic purpura (ITP). Nouvelle Revue Française d’Hématologie 28: 275–279, 1986PubMedGoogle Scholar
  11. Arrowsmith JB, Dreis M. Thrombocytopenia after treatment with danazol. Correspondence. New England Journal of Medicine 315: 585, 1986Google Scholar
  12. Ballin A, Andrew M, Ling E, Perlman M, Blanchette V, et al. High-dose intravenous gammaglobulin therapy for neonatal autoimmune thrombocytopenia. Journal of Pediatrics 112: 789–792, 1988PubMedGoogle Scholar
  13. Barton JC, Herrera GA, Galla JH, Bertoli LF, Work J, et al. Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. American Journal of Medicine 82(3): 624–629, 1987PubMedGoogle Scholar
  14. Baumann MA, Menitove JE, Aster RH, Anderson T. Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion. Annals of Internal Medicine 104: 808–809, 1986PubMedGoogle Scholar
  15. Becker T, Kuenzlen E, Salama A, Mertens R, Kiefel V, et al. Treatment of childhood idiopathic thrombocytopenic purpura with Rhesus antibodies (anti-D). European Journal of Pediatrics 145: 166–169, 1986PubMedGoogle Scholar
  16. Bellucci S, Bordessoule D, Coiffier B, Tabah I. Interferon alpha-2b therapy in adult chronic thrombocytopenic purpura (ITP). Correspondence. British Journal of Haematology 73: 578–579, 1989Google Scholar
  17. Bellucci S, Charpak Y, Chastang C, Tobelem G, the Cooperative Group on Immune Thrombocytopenic Purpura. Low doses v conventional doses of corticoids in immune thrombocytopenic purpura (ITP): results of a randomized clinica trial in 160 children, 223 adults. Blood 71: 1165–1169, 1988PubMedGoogle Scholar
  18. Boshkov LK, Kelton JG. Use of intravenous gammaglobulin as an immune replacement and an immune suppressant. Transfusion Medicine Review 3: 82–120, 1989Google Scholar
  19. Boughton BJ, Chakraverty R, Baglin TP, Simpson A, Galvin G, et al. The treatment of chronic idiopathic thrombocytopenia with anti-D (Rho) immunoglobulin: its effectiveness, safety and mechanism of action. Clinical and Laboratory Haematology 10: 275–284, 1988PubMedGoogle Scholar
  20. Brox AG, Howson-Jan K, Fauser AA. Treatment of idiopathic thrombocytopenic purpura with ascorbate. British Journal of Haematology 70: 341–344, 1988PubMedGoogle Scholar
  21. Bussel JP, Berkowitz RL, McFarland JG, Lynch L, Chitkara U. Antenatal treatment of neonatal alloimmune thrombocytopenia. New England Journal of Medicine 319: 1374–1378, 1988aPubMedGoogle Scholar
  22. Bussel JB, Pham LC, Aledort L, Nachman R. Maintenance treatment of adults with chronic refractory immune thrombocytopenic purpura using repeated intravenous infusions of gammaglobulin. Blood 72: 121–127, 1988bPubMedGoogle Scholar
  23. Bussel JB, Saal S, Gordon B. Combined plasma exchange and intravenous gammaglobulin in the treatment of patients with refractory immune thrombocytopenic purpura. Transfusion 28: 38–41, 1988cPubMedGoogle Scholar
  24. Caplan SN, Berkman EM. Immunosuppressive therapy of idiopathic thrombocytopenic purpura. Medical Clinics of North America 60: 971–986, 1976PubMedGoogle Scholar
  25. Cattaneo M, Gringeri A, Capitanio AM, Santagostino E, Mannucci PM. Anti-D immunoglobulin for treatment of HIV-related immune thrombocytopenic purpura. Correspondence. Blood 73: 357, 1989Google Scholar
  26. Chong BH, Ismail F, Cade J, Gallus AS, Gord S, et al. Heparininduced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 73: 1592–1596, 1989PubMedGoogle Scholar
  27. Cimo PL, Aster RH. Post-transfusion purpura: successful treatment by exchange transfusion. New England Journal of Medicine 287: 290–292, 1972PubMedGoogle Scholar
  28. Clarkson SB, Bussell JB, Kimberly RP, Valinsky JE, Nachman RL, et al. Treatment of refractory thrombocytopenic purpura with an anti-Fcτ-receptor antibody. New England Journal of Medicine 314: 1236–1239, 1986PubMedGoogle Scholar
  29. Cola B, Tonielli E, Sacco S, Brulatti M, Franchini A. Surgical treatment of chronic idiopathic thrombocytopenic purpura: results in 107 cases. International Surgery 71: 195–198, 1986PubMedGoogle Scholar
  30. Cole CW, Bormanis J. Ancrod: a practical alternative to heparin. Journal of Vascular Surgery 8: 59–63, 1988PubMedGoogle Scholar
  31. Coon WW. Splenectomy for idiopathic thrombocytopenic purpura. Surgery, Gynecology and Obstetrics 164: 225–229, 1987PubMedGoogle Scholar
  32. Del Principe D, Menichelli A, Mori PG, De Mattia D, Mancuso G, et al. Phase II trial of methylprednisolone pulse therapy in childhood chronic thrombocytopenia. Acta Haematologica (Basel) 77: 226–230, 1987Google Scholar
  33. Derycke M, Dreyfus M, Ropert JC, Tchernia G. Intravenous immunoglobulin for neonatal isoimmune thrombocytopenia. Archives of Diseases in Childhood 60: 660–669, 1985Google Scholar
  34. DiFino SM, Lachant NA, Kirshner JJ, Gottlieb AJ. Adult idiopathic thrombocytopenic purpura: clinical findings and response to therapy. American Journal of Medicine 69: 430–442, 1980PubMedGoogle Scholar
  35. Dunn NL, Maurer HM. Prednisone treatment of acute idiopathic thrombocytopenic purpura of childhood. American Journal of Pediatric Hematology/Oncology 6: 159–164, 1984PubMedGoogle Scholar
  36. Fehr J, Hofmann V, Kappeier U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gammaglobulin. New England Journal of Medicine 306: 1254–1258, 1982PubMedGoogle Scholar
  37. Fenaux P, Caulier MT, Hirschauer MC, Beuscart R, Goudemand J, et al. Reevaluation of the prognostic factors for splenectomy in chronic idiopathic thrombocytopenic purpura (ITP): a report on 181 cases. European Journal of Haematology 42: 259–264, 1989PubMedGoogle Scholar
  38. Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. New England Journal of Medicine 320: 974–980, 1989PubMedGoogle Scholar
  39. Gibson J, Richard KA, Bautovich G, May J, Kronenberg H. Management of splenectomy failures in chronic immune thrombocytopenic purpura: role of accessory splenectomy. Australian and New Zealand Journal of Medicine 16: 695–698, 1986PubMedGoogle Scholar
  40. Guthrie Jr TH, Oral A. Immune thrombocytopenia purpura: a pilot study of Staphylococcal protein A immunomodulation in refractory patients. Seminars in Hematology 26 (Suppl. 1): 3–XX, 1989PubMedGoogle Scholar
  41. Handin RI, Stossel TP. Effect of corticosteroid therapy on the phagocytosis of antibody-coated platelets by human leukocytes. Blood 51: 771–779, 1978PubMedGoogle Scholar
  42. Hill W, Landgraf R. Successful treatment of amegakaryocytic thrombocytopenic purpura with cyclosporine. New England Journal of Medicine 312: 1060–1061, 1985PubMedGoogle Scholar
  43. Hollenberg JP, Subak LL, Ferry Jr JJ, Bussel JB. Cost-effectiveness of splenectomy versus intravenous gamma globulin in treatment of chronic immune thrombocytopenic purpura in childhood. Journal of Pediatrics 112: 530–539, 1988PubMedGoogle Scholar
  44. Hoyle C, Darbyshire P, Eden OB. Idiopathic thrombocytopenia in childhood: Edinburgh experience 1962–82. Scottish Medical Journal 31: 174–179, 1986PubMedGoogle Scholar
  45. Ikkala E, Kivilaakso E, Kotilainen M, Hastbacka J. Treatment of idiopathic thrombocytopenic purpura in adults: long-term results in a series of 41 patients. Annals of Clinical Research 10: 83–86, 1978PubMedGoogle Scholar
  46. Imbach P, Wagner HP, Berchtold W, Gaedicke G, Hirt A, et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 2: 464–468, 1985PubMedGoogle Scholar
  47. Jacobs P, Wood L, Dent DM. Results of treatment in immune thrombocytopenia. Quarterly Journal of Medicine 58: 153–165, 1986PubMedGoogle Scholar
  48. Jayabose S, Patel P, Inamdar S, Brilliant R, Mamtani R. Use of intravenous methylprednisolone in acute idiopathic thrombocytopenic purpura. American Journal of Pediatric Hematology/Oncology 9: 133–135, 1987PubMedGoogle Scholar
  49. Jim RTS. Therapeutic use of colchicine in thrombocytopenia. Hawaii Medical Journal 45: 221–226, 1986PubMedGoogle Scholar
  50. Joseph A, Evans DI. Immunosuppressive treatment of idiopathic thrombocytopenic purpura in children. Acta Paediatrica Scandinavica 71: 467–469, 1982PubMedGoogle Scholar
  51. Kaplan C, Daffos F, Forestier F, Cox WL, Lyon-Caen D, et al. Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets. Blood 72: 340–343, 1988PubMedGoogle Scholar
  52. Kelsey PR, Schofield KP, Geary CG. Refractory idiopathic thrombocytopenic purpura (ITP) treated with cyclosporine. Correspondence. British Journal of Haematology 60: 197–198, 1985Google Scholar
  53. Kelton JG. Management of the pregnant patient with idiopathic thrombocytopenic purpura. Annals of Internal Medicine 99: 796–800, 1983PubMedGoogle Scholar
  54. Kelton JG. The interaction of IgG with reticuloendothelial cells: biological and therapeutic implications. In Garratty G (Ed.) Current concepts in transfusion therapy, pp. 51–107, American Association of Blood Banks, Arlington, 1985Google Scholar
  55. Kelton JG, Inwood MJ, Barr RM, Effer SB, Hunter D, et al. The prenatal prediction of thrombocytopenia in infants of mothers with clinically diagnosed immune thrombocytopenia. American Journal of Obstetrics and Gynecology 144: 449–454, 1982PubMedGoogle Scholar
  56. Kelton JG, McDonald JW, Barr RM, Walker I, Nicholson W, et al. The reversible binding of vinblastine to platelets: implications for therapy. Blood 57: 431–438, 1981PubMedGoogle Scholar
  57. Kim HC, Park CL, Cowan III JH, Fattori FD, August CS. Massive intravascular hemolysis associated with intravenous immunoglobulin in bone marrow transplant recipients. American Journal of Pediatric Hematology/Oncology 10: 69–74, 1988PubMedGoogle Scholar
  58. Kim KS. Use of intravenous immunoglobulin in bacteria diseases. Annals of Internal Medicine 107: 369–371, 1987Google Scholar
  59. Kitchen CS. Amelioration of endothelial abnormalities by prednisone in experimental thrombocytopenia in the rabbit. Journal of Clinical Investigation 60: 1129–1134, 1977Google Scholar
  60. Kochupillai V, Nundy S, Sharma S. Idiopathic thrombocytopenic purpura in adults: response to corticosteroids and splenectomy. Journal of the Association of Physicians of India 34: 555–558, 1986PubMedGoogle Scholar
  61. Königswieser H. Incidence of serious infections after splenectomy in children. Progress in Pediatric Surgery 18: 173–181, 1985PubMedGoogle Scholar
  62. Krause JR. Chronic idiopathic thrombocytopenic purpura (ITP): development of acute non-lymphocytic leukemia subsequent to treatment with cyclophosphamide. Medical and Pediatric Oncology 10: 61–65, 1982PubMedGoogle Scholar
  63. Lederman HM, Roifman CM, Lavi S, Gelfand EW. Corticosteroids for prevention of adverse reactions to intravenous immune serum globulin infusions in hypogammaglobulinemic patients. American Journal of Medicine 81: 443–446, 1986PubMedGoogle Scholar
  64. Leroy J, Leclerc MH, Delahousse B, Guerois C, Foloppe P, et al. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216). Seminars in Thrombosis and Hemostasis 11: 326–329, 1985PubMedGoogle Scholar
  65. Mazzucconi MG, Francesconi M, Fidani P, Di Nucci G, Gandolfo GM, et al. Treatment of idiopathic thrombocytopenic purpura (ITP): results of a multicentric protocol. Haematologica (Pavia) 70: 329–336, 1985Google Scholar
  66. McMillan R, Longmire R, Yelenosky R. The effect of corticosteroids on human IgG synthesis. Journal of Immunology 116: 1592–1595, 1976Google Scholar
  67. McMillan R, Longmire RL, Yelenosky R, Smith RS, Craddock CG, et al. Immunoglobulin synthesis in vitro by splenic tisue in idiopathic thrombocytopenic purpura. New England Journal of Medicine 286: 681–684, 1972PubMedGoogle Scholar
  68. Mueller-Eckhardt C, Kiefel V. High-dose IgG for post-transfusion purpura-revisited. Blut 57: 163–167, 1988PubMedGoogle Scholar
  69. Mueller-Eckhardt C, Salama A. Anti-Rh(D) immunoglobulin for immune thrombocytopenic purpura. Correspondence. Lancet 2: 50, 1986Google Scholar
  70. Neppert J, Clemens M, Mueller-Eckhardt C. Immune phagocytosis inhibition by commercial immunoglobulins. Blut 52: 67–72, 1986PubMedGoogle Scholar
  71. Nesher G, Dollberg L, Zimran A, Hershko C. Hepatosplenic peliosis after danazol and glucocorticoids for ITP. Correspondence. New England Journal of Medicine 312: 242, 1985Google Scholar
  72. Oksenhendler E, Bierling P, Brossard Y, Schenmetzler C, Girard PM, et al. Anti-RH immunoglobulin therapy for human immunodeficiency virus-related immune thrombocytopenic purpura. Blood 71: 1499–1502, 1988PubMedGoogle Scholar
  73. Oksenhendler E, Bierling P, Farcet JP, Rabian C, Seligmann M, et al. Response to therapy in 37 patients with HIV-related thrombocytopenic purpura. British Journal of Haematology 66: 491–495, 1987PubMedGoogle Scholar
  74. O’Neal BJ, McDonald JC. The risk of sepsis in the asplenic adult. Annals of Surgery 194: 775–778, 1981PubMedGoogle Scholar
  75. Pettersson T, Riska H, Nordström D, Honkanen E. Plasmapheresis for idiopathic thrombocytopenic purpura unresponsive to intravenous immunoglobulin. Correspondence. European Journal of Haematology 39: 92–93, 1987Google Scholar
  76. Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: multicentric trial of the Cooperative Latin American Group on Hemostasis and Thrombosis. Blood 64: 1179–1183, 1984PubMedGoogle Scholar
  77. Proctor SJ, Jackson G, Carey P, Stark A, Finney R, et al. Improvement of platelet counts in steroid-unresponsive idiopathic immune thrombocytopenic purpura after short-course therapy with recombinant α 2b interferon. Blood 74: 1894–1897, 1989PubMedGoogle Scholar
  78. Quiquandon I, Fenaux P, Caulier MT, Pagniez D, Huart JJ, et al. Re-evaluation of the role of azathioprine in the treament of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. British Journal of Haematology 74: 223–228, 1990PubMedGoogle Scholar
  79. Rosse WF. Whatever happened to vinca-loaded platelets? New England Journal of Medicine 310: 1051–1502, 1984PubMedGoogle Scholar
  80. Russo D, Gugliotta L, Mazzucconi MG, Isacchi G, Tonielli E, et al. Long-term results of splenectomy in adult chronic idiopathic thrombocytopenic purpura. Haematologica (Pavia) 72: 445–449, 1987Google Scholar
  81. Salama A, Kiefel V, Amberg R, Mueller-Eckhardt C. Treatment of autoimmune thrombocytopenic purpura with Rhesus antibodies (anti-Rho (D)). Blut 49: 29–35, 1984PubMedGoogle Scholar
  82. Salama A, Kiefel V, Mueller-Eckhardt C. Effect of IgG anti-Rho (D) in adult patients with chronic autoimmune thrombocytopenia. American Journal of Hematology 22: 241–250, 1986PubMedGoogle Scholar
  83. Saleh M, Court W, Huster W, Shaw D, LoBuglio A. Effect of commercial immunoglobulin G preparation on human monocyte Fc-receptor dependent binding of antibody coated platelets. British Journal of Haematology 68: 47–51, 1988PubMedGoogle Scholar
  84. Schreiber AD, Chien P, Tomaski A, Cines DB. Effect of danazol in immune thrombocytopenic purpura. New England Journal of Medicine 316: 503–508, 1987PubMedGoogle Scholar
  85. Schroeder JO, Euler HH, Löffler H. Synchronization of plasma-pheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Annals of Internal Medicine 107: 344–346, 1987PubMedGoogle Scholar
  86. Schwartz SI, Hoepp LM, Sachs S. Splenectomy for thrombocytopenia. Surgery 88: 497–506, 1980PubMedGoogle Scholar
  87. Scott JR, Cruikshank DP, Kochenour NK, Pitkin RM, Warenski JC. Fetal platelet counts in the obstetric management of immunologic thrombocytopenic purpura. American Journal of Obstetrics and Gynecology 136: 495–499, 1980PubMedGoogle Scholar
  88. Simon M, Jouet JP, Fenaux P, Pollet JP, Walter MP, et al. The treatment of adult idiopathic thrombocytopenic purpura: infusion of vinblastine in ITP. European Journal of Haematology 39: 193–196, 1987PubMedGoogle Scholar
  89. Slichter SJ. Post-transfusion purpura: response to steroids and association with red blood cell and lymphocytotoxic antibodies. British Journal of Haematology 50: 599–605, 1982PubMedGoogle Scholar
  90. Strother SV, Zuckerman KS, LoBuglio AF. Colchicine therapy for refractory idiopathic thrombocytopenic purpura. Archives of Internal Medicine 144: 2198–2200, 1984PubMedGoogle Scholar
  91. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII (anti-haemophilic factor) by high-dose intravenous gammaglobulin. Lancet 2: 765–768, 1984PubMedGoogle Scholar
  92. Thomas DP. Reducing the risk of virus transmission of blood products. British Journal of Haematology 70: 393–395, 1988PubMedGoogle Scholar
  93. Thompson RL, Moore RA, Hess CE, Wheby MS, Leavell BS, et al. Idiopathic thrombocytopenic purpura: long-term results of treatment and the prognostic significance of response to corticosteroids. Archives of Internal Medicine 130: 730–734, 1972PubMedGoogle Scholar
  94. Van Hoff J, Ritchey AK. Pulse methylprednisolone therapy for acute childhood idiopathic thrombocytopenic purpura. Journal of Pediatrics 113: 563–566, 1988PubMedGoogle Scholar
  95. Velu TJ, Debusscher L, Stryckmans PA. Ciclosporine for the treatment of refractory idiopathic thrombocytopenic purpura. Correspondence. European Journal of Haematology 38: 95, 1987Google Scholar
  96. Verhoef GEG, Boonen S, Boogaerts MA. Ascorbate for the treatment of refractory idiopathic thrombocytopenia purpura. Correspondence. British Journal of Haematology 74: 234, 1990Google Scholar
  97. Warkentin TE, Kelton JG. Heparin and platelets. Hematology-Oncology Clinics of North America 4: 243–264, 1990Google Scholar
  98. Weinblatt ME, Kochen J, Ortega J. Danazol for children with immune thrombocytopenic purpura. American Journal of Diseases of Childhood 142: 1317–1319, 1988Google Scholar
  99. Weinerman B, Maxwell I, Hryniuk W. Intermittent cyclophosphamide treatment of autoimmune thrombocytopenia. Canadian Medical Association Journal 111: 1100–1102, 1974PubMedGoogle Scholar
  100. Wentz AC. Adverse effects of danazol in pregnancy. Annals of Internal Medicine 96: 672–673, 1982PubMedGoogle Scholar
  101. Wood L, Jacobs P. Durable response to etoposide-loaded platelets in refractory immune thrombocytopenic purpura: a case report. American Journal of Hematology 27: 63–64, 1988PubMedGoogle Scholar
  102. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Correspondence. Lancet 2: 217–218, 1986Google Scholar
  103. Yoshida K, Wakui H, Mamiya S, Yamaguchi A, Miura AB. Bolus methylprednisolone therapy in adult idiopathic thrombocytopenic purpura. Japanese Journal of Medicine 26: 172–175, 1987PubMedGoogle Scholar

Copyright information

© Adis International Limited 1990

Authors and Affiliations

  • Theodore E. Warkentin
    • 1
    • 2
    • 3
  • John G. Kelton
    • 1
    • 2
    • 3
  1. 1.Department of PathologyMcMaster University Medical CentreHamiltonCanada
  2. 2.McMaster University Medical CentreHamiltonCanada
  3. 3.Canadian Red Cross Blood Transfusion ServiceHamilton CentreHamiltonOntarioCanada

Personalised recommendations